The Wall Street Journal: Catalent to buy Paragon Bioservices in $1.2 billion gene-therapy-drug deal
Contract drug manufacturer Catalent Inc. agreed to buy closely held Paragon Bioservices Inc. for $1.2 billion, according...
Search by tag: bioservices